Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | ERN1 | O75460 | 3/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8593124 | 0.88 | NPSR1 (0.69) | NPSR1ERN1ROCK2CYP3A4CYP3A5 | |
| SCHEMBL164968 | 0.83 | ALDH1A1 (0.60) | HPGDGAAKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL1754131 | 0.81 | ATM (0.67) | NPSR1KMT2AATMHDAC8HDAC6 | |
| SCHEMBL30522592 | 0.81 | ATM (0.67) | NPSR1KMT2AATMHDAC8HDAC6 | |
| SCHEMBL13753397 | 0.81 | NPSR1 (0.61) | NPSR1ERN1ROCK2CYP3A4CYP3A5 | |
| SCHEMBL14355565 | 0.81 | NPSR1 (0.61) | NPSR1ERN1ROCK2CYP3A4CYP3A5 | |
| SCHEMBL165801 | 0.81 | KDM4E (0.61) | NPSR1ERN1ROCK2CYP3A4CYP3A5 | |
| SCHEMBL13702108 | 0.81 | ERN1 (0.62) | NPSR1ERN1ROCK2CYP3A4CYP3A5 | |
| SCHEMBL162858 | 0.80 | HDAC8 (0.68) | HPGDGAAKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL3650360 | 0.80 | NPSR1 (0.59) | NPSR1ERN1ROCK2CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-8765789-B2 | 2-pyridinecarboxamide derivatives | MSD K.K. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-8344003-B2 | 2-pyridinecarboxamide derivatives | MSD K. K. (JP) | 2013-01-01 | — | — | US | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | MSD K.K. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-7629362-B2 | 2-pyridine carboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | NPSR1 4694/4885ERN1 1210/4885ROCK2 3887/4885 |
| US-20130085156-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | NPSR1 3400/4885ERN1 1144/4885ROCK2 3300/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | NPSR1 3341/4885ERN1 1144/4885ROCK2 3307/4885 |
| US-20100041660-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | GCKR, GCK, HK2 | NPSR1 3400/4885ERN1 1144/4885ROCK2 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.